glp 1 pediatric obesity trials aim to expand GLP-1 weight loss drugs to younger children GLP-1s for Childhood Obesity: Ready

Los agonistas de los receptores GLP-1 y GIP son tratamientos innovadores desarrollados inicialmente para la diabetes, pero que ahora se utilizan para tratar la obesidad

TRICARE covers GLP-1 drugs, but strict rules apply

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

This supports that pharmacies are permitted to compound GLP-1 drugs under section 503A of the Act, provided they adhere to specific conditions outlined by the FDA

Multiple studies highlight its potential applications in prevention

The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF